Serious after-effects no more likely after a third COVID-19 vaccine

Embargoed until: Publicly released: 2022-04-15 01:00

International

Researchers delved into electronic health records from 48,000 Americans, finding people who had three Pfizer or Moderna vaccine shots (using the same vaccine) weren’t more likely to report serious adverse effects like myocarditis or anaphylaxis, than before vaccination or after earlier doses. Milder reactions - such as fatigue or nausea - were more frequent following the third shot compared to the earlier two. The authors say their study suggests a third vaccine may be safe, but it could under-represent people who reacted badly to earlier shots due to reluctance to seek a third one.

Media release

From:

Attachments

Note: Not all attachments are visible to the general public. Research URLs will go live after the embargo ends.

Research JAMA, Web page This link will be live at the embargo time

Journal/
conference: JAMA Network Open

Research:Paper

Organisation/s: nference (a company that collaborates with health organisations on data science initiatives), Mayo Clinics in various states including Minnesota, Florida, Arizona (US)

Funder: Conflict of Interest Disclosures: Drs Niesen and Soundararajan reported being employees of nference, which is collaborating with biopharmaceutical companies on data science initiatives unrelated to this study. Dr Pawlowski reported receiving personal fees from nference outside the submitted work. Dr O’Horo reported receiving grants from nference and Mitre, receiving consulting fees from Bates College, and owning privately purchased stock from Doximity outside the submitted work. Dr Silvert reported receiving personal fees from nference as an employer during the conduct of the study and outside the submitted work. Dr Lenehan reported employment by nference. Dr Virk reported receiving personal fees from Moderna outside the submitted work. Dr Swift reported receiving grants from the Pfizer Healthcare Worker Exposure Response and Outcomes (HEROE) vaccine registry via Duke University outside the submitted work. Dr Badley reported receiving grants from the National Institute of Allergy and Infectious Diseases, Amfar, and Mayo Clinic; consulting fees for AbbVie, Gilead Sciences, Freedom Tunnel, PineTree Therapeutics, Primmune Therapeutics, Immunome, MarPam Pharma, Rion, Symbiosis, and Flambeau Diagnostics; and personal fees from Corvus Pharmaceuticals, Equillium, CSL Behring, Excision BioTherapeutics, ReachMD, PeerVoice, and Medscape; owning equity for scientific advisory work in Zentalis, Rion, and nference; and serving as founder and president of Splissen Therapeutics. No other disclosures were reported.

Media Contact/s

Contact details are only visible to registered journalists.